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Abstract
AIDS still persists as a relevant disease in public health and scientific research. There 
have been significant advances in HIV research, notably the development of an effective 
regimen in antiretroviral therapy. However, the emergence of drug resistance has facili-
tated continued research in administration of therapy and the development of new anti-
retroviral drugs. In spite of nearly three (3) decades of intensive research, there still is not 
an effective vaccine against HIV-1. Animal models have been a crucial tool in drug dis-
covery process for invasive investigation of HIV disease mainly in preclinical evaluation 
of drugs and vaccines. This undoubtedly is an integral part of successes so far achieved 
in HIV/AIDS research. Advances in both non-human primate and murine model immu-
nogenetics in response to recombinant viruses have greatly increased the options of ani-
mal models available for research. Understanding the pros and cons of these models is 
imperative for animal study design that could further the development of vaccines and 
antiretroviral therapies for HIV prevention and treatment of AIDS patients.
Keywords: HIV/AIDS, animal models, clinical trials, humanized mouse model, 
candidate vaccine testing, primates, HIV reserviour
1. Introduction
To understand the etiology, and mechanistic approach to eliminating disease processes and 
its attendant challenges, animal models have been indispensable in shortening the length of 
time, resources and complications inherent in disease prevention and drug discovery. Animal 
models, however, play a central role in the extensive research of HIV infection since the early 
1980 [1].
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Numerous animal species could be infected with HIV, but hardly do they develop AIDS-like 
syndrome that approximates humans. Several reasons have been adduced to this including 
decreased viral infectivity factor, efficiency of HIV replication in the animal species and host 
immunologic response proteins thus referred to as host factors [2].
Evolutionarily, the Chimpanzee had been believed to be close to humans thus exploited in AIDS 
research. Scientists later understood that HIV does not infect the Chimps but SIV besides the high 
cost attached to its use in HIV diseases research. Maintaining a primate research facility tends to 
incur huge cost, and most centers are being shut down around the world. These animal models 
are used to study diseases and infections of lentiviruses specifically Feline Immunodeficiency 
Virus (FIV) in cats, and Simian Immunodeficiency Virus (SIV) in monkeys. However, these 
viruses are distinct from HIV and have the problem associated with extrapolating data from 
experimental studies [2]. Consequently, researchers resorted to intensive search for alternative 
experimental model for HIV infection. Mouse, being 90% genetically similar to humans poses as 
a ‘go’ option hence the intensive and successful development of mouse models for HIV research.
It is worth mentioning though that testing the effectiveness and toxicity of anti-HIV medica-
tions such as anti-proteases and HIV-1 Reverse Transcriptase inhibitors (AZT, and 3TC) are 
experimentally conducted using cell culture techniques derived from human white blood 
cells [3–5]. No such mechanistic model for HIV pathobiology has been created [6].
Murine experimental HIV models are putatively regarded as the most extensive approach appro-
priate for evaluating the safety, efficacy and salient aspects of novel drugs or vaccine candidates. 
These models, to a high degree, have achieved remarkable success thus bridging the gap between 
preclinical and clinical evaluations on humans. Similarly, they are effectively utilized in toxico-
logical evaluations of drugs, testing of novel anti-HIV small and interfering molecules and pre 
clinical trials. Bearing that humans cannot be used experimentally, continued development of 
the animal subjects for use in research has seen tremendous improvement and modifications [2].
2. Initiation and progression of HIV infection
The so-called latent period after the infection by the virus does not mean the virus is inactive 
[7]. Apart from humans, HIV-1 naturally infects a small number of nonhuman primate spe-
cies, notably chimpanzees, which have been known to host the virus. Development of AIDS 
from HIV progression only occurs in humans [8, 9].
To gain insights in the transmission, pathobiology and progression of HIV infection, develop-
ment of an animal model of HIV-induced immunodeficiency becomes mandatory. Several 
approaches were adopted to circumvent species tropism, that is, finding a similar lentivirus 
specific to other species that can cause similar symptoms, that is, immune deficiencies as a 
results of affinities to CD4+ T-cells and macrophages [9].
2.1. In humans
HIV-1 mainly infects through the genital mucosa with persistence chronic infection even 
when the virus triggers a notably strong cellular and humoral (both innate and adaptive) 
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immunity. The reason for this action may stem from the virus genomic integration and 
subsequent cellular latent activity coupled with its extreme genetic variability, which pro-
vides a consistent immune specific escape. It is known that HIV-specific CD8+ lymphocytes 
are key players involved in initial decrease or suppression of viremia during acute HIV 
infection conversely this becomes highly dysfunctional and burdened under the strenous 
condition of chronic viral antigenic persistency [10, 11]. Viral neutralizing antibodies (Abs) 
are similarly triggered which also accompany immune escape. In some individuals, par-
ticularly elite HIV controllers or suppressors, they develop broad neutralizing Abs thereby 
have an effective control of the virus [12].
HIV infection is hallmarked by massive reduction of CD4+ T cells. During the primary HIV 
infection, the effector memory CD4+ T cells present in the gut mucosa are consistently and 
preferentially depleted [13]. The immunopathogenic presentations, in addtion to the systemic 
and chronic state of immune activation, are believed to contribute directly to HIV disease 
progression [14]. As a result, persistent antigenic stimulation presents a dysfunctional T-cell 
population with a loss of functional potential in cytokine production and cytotoxic activity, 
and the ability to proliferative in response to antigen stimulation. It is believed that this loss 
of immune balance between Th17 and regulatory T cells (Treg) during HIV disease progres-
sion may be the reason for the permeabilization of gut integrity and the pathogenesis of HIV.
Microbial translocation caused by gut permeability is thought to contribute to systemic 
immune stimulation seen in chronic HIV infection [15]. Additionally, hyper-responsiveness 
of plasmacytoid DCs during the cause of primary HIV infection, typically results in type-1 
IFN excess production which contributes to systemic immune stimulation and HIV-1 disease 
progression [16].
Previous studies suggest a relationship between CD8+ T cells and the control of chronic HIV 
replication similar to that of simian immunodeficiency virus (SIV) viremia in non-human 
primates [17]. There are also rare individuals who control HIV-1 replication to levels which 
the virus cannot be detected also known as elite controllers with attendant characteristics [18]. 
This phenotype shows a strong association with certain MHC class I alleles with HIV-specific 
CD8+ T cells demonstrating superior cytotoxic capacity to kill any HIV-infected target.
Two examples of markers in HIV-1+ patients associated with T-cell exhaustion are Programmed 
Death-1 (PD-1) and T cell immunoglobulin and mucin domain 3 (Tim-3), which likely are 
caused by consistent antigenic stimulation [19]. These two molecules have been shown to par-
ticipate in the downregulation of host immune responses, playing a key role in sustenance of T 
cell tolerance. It is obvious that Tim-3 is upregulated on virus-specific CD8+ T cells in subjects 
with chronic progressive HIV infection [19]. Similarly, another report stated the upregulation 
of Tim-3 on antigen-specific CD8+ T cells in subjects with active TB [20], buttressing similarity 
in the role played by the inhibitory receptor/ligand interactions with respect to modulation of 
host immunity to both HIV and M. tuberculosis infections in humans.
2.2. In primates
Several non-human primates are naturally infected with simian T lymphotropic virus (STLV) 
types I and III. The exogenous type C retrovirus isolated from macaque monkeys in captivity 
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reported in the USA with an immune deficiency syndrome otherwise known as simian AIDS 
has been termed STLV-III mac. It is worthy to note that STLV types I and III are similar and/
or related to the human T lymphotropic viruses (HTLV-I and LAV/HTLV-III) the causative 
agent(s) for AIDS. The striking similarities include growth characteristics, similar size of viral 
structural proteins, morphology, T4 cell tropism and serological cross reactivity of viral pro-
teins [21]. The residing proteins found in the simian virus also have similar molecular weight 
with respect to the gag and env encoded proteins of LAV/HTLV-III [22]. Both are recognized 
by reference LAV/HTLV-III human serum and monoclonal antibodies to the core protein, 
p24, of the human virus. These proteins are basic and have relevant information needed in 
the development of candidate vaccine, rapid diagnostics and elucidation of HIV virology [21]. 
Knowledge of the molecular structure and pathobiology of simian viruses yielded a wealth of 
information and was very useful in the study of the HIV and AIDS in humans [21].
2.3. In rodents
In addition to looking for other lentiviruses, rodents were genetically engineered so 
that their cells could express both the human version of the CD4 receptor as well as the 
chemokine co-receptors to which HIV-1 binds, notably the main route of entry to target 
cells [23]. The envelope glycoprotein 120 (gp120) domiciled on the surface of the HIV-1 
virus fuses with the host target cell membrane specifically invoking a cascade of activity 
involving the CD4+ receptors and chemokines co-receptors thus initiates viral entry. In 
successfully developed transgenic mice, however, the gp120 will not successfully bind to 
CD4-expressing T cells thus preventing targeted cell infection. Replacement of the gp120 
coding region of the HIV with gp80 region obtained from the murine leukemia virus results 
in altered virus thus overcoming the problem. This chimeric HIV-1 clone could infect con-
ventional mice cells, but not human cells. Although this has been extensively adopted in 
research, these models could not produce some disease progression seen in humans, for 
example, neuro-HIV disease [9].
Humanized mice model also known as humice are mice carrying functioning human genes, 
cells, tissues, and/or organs engraftment mostly on genetically modified mouse background. 
They replicate the human HIV immune responses and are currently used to study mecha-
nisms of immune activation, mucosal transmission and prevention, immune pathogenesis 
and anti-viral drug development.
2.4. Developmental perspectives of HIV animal models
The development of fitting animal models is seen as one of the most important challenges 
in studies of co-infection, since HIV does not cause disease in rodents and in non-human 
primates [24].
Lentiviruses specific to other species that also compromise the immune systems in ways simi-
lar to HIV-1 have been useful in providing information about the pathogenicity of the virus. 
In spite of the similarities to HIV, there are species-specific differences in their respective gene 
products as well as the pathogenesis of the disease fueling the drive for search of better mod-
els of HIV disease control.
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3. Defining animal models
3.1. Macaques
SIV in macaques follow a disease course that is similar to HIV in humans. This is useful since 
it can be exploited for evaluation of drug/vaccine candidates closely related to that being 
developed for respective human HIV infection. The model thus provides leading and insight-
ful results in and related to drug safety and efficacy of prospective candidates [1]. Certain ani-
mal models have been developed over the years through intensive research for insightful and 
revealing studies on HIV/AIDS and associated cancers. These include both specific rat and 
mouse models designed for HIV pathogenesis and candidate vaccine development. Scientists 
have albinitio created the SIV non-human primate(NHP) model (Figure 1), for example, the 
Indian-origin rhesus macaque (Macaca mulatta), Cynomolgous macaque (M. fascicularis), and 
pigtailed macaque (M. nemestrina), for same purposes including development of microbi-
cides. These models are useful in elucidating the mechanism of AIDS pathogenesis as well as 
in preclinical testing of novel drugs directed at HIV infection and cancer [1, 25, 26].
SIV infection in macaques has been used as a model for AIDS since it was established that 
non-human primates are resistant to infection by HIV (Table 1). Simply put, SIV is a ret-
rovirus causing immunodeficiency similar to AIDS in Asian macaques. More importantly, 
Macaques also develop TB that is very similar to that of humans, other notable similarities 
in viral activity and disease manifestation include cavitary lung disease and necrotic lession. 
The TB latency seems in contrast to humans to have only a small proportion of lately infected 
Macques develop reactivation [27] though it develops persistent Mycobacterium bovis bacillus 
Calmette Guerin (BCG) [28] and M. tuberculosis co-infection [29].
Figure 1. Historical trend and impact of HIV/AIDS research in NHPs.
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Animal model Species Cons Pros Retroviral study sub-types
Macaques Rhesus
macaques
(Macaca mulatta)
• Resistant to HIV. SIV shows discrepancies to HIV 
which Macaques are resistance to especially with 
respect to the association of TB reactivation and viral 
load.
• Low turnaround of the model.
• Availability of some rhesus macaques depends on 
domestic breeding capacity and skill.
• Have poorly characterized MHC allelic profiles and 
may not be suitable for vaccine studies.
• May not be appropriate for comparative menstrual 
cycle-related SIV/SHIV studies.
• Can be infected with SIV which 
compromises immunity
• Ability to causes secondary 
complications similar to HIV in 
humans.
• Intravenous, intrarectal, intravagi-
nal and penile-exposure models 
are established
• Studies of SIV/TB co-infection 
models.
• Indian macaques have well char-
acterized MHC allelic profiles thus 
suitable for as a model for vaccine 
candidates.
SIVmac239
SIVsmPBj6.9
SIVsmPBj6.6
SIVPBj14
SIVmac316
SIVsmE543–3
SIVsmE660
SIVmac251
RT-SHIV
SHIV-SF162P3
Pigtail
macaques (Macaca 
nemestrina
• SIVmac infections typically does not refelct HIV-1 
infection and is more aggressive.
• Usually more expensive to maintain
• Not an established model for evaluation of vaccine 
candidates
• In the female vaginal ecology, 
physiology and intravaginal virus 
challenge is similar to that of 
human.
• SIV/SHIV and STI co-infection 
models can be studied.
SIVmac251 +
SHIV/17E-Fr
SIVmne
SIVmneCl8
SIVmne170
SIVmne027
Cynomologus
macaques
(M. fascicularis)
• Difficult in sample collection due to smaller size.
• Exhibit low viral loads.
• Its suitability for vaccine studies is low.
• Has smaller size therefore, easier 
to handle.
• It is more readily available.
RT-SHIV
SIVmac251
Baboons • Limited HIV replication activity in monocytes or 
macrophages, CSF or brain
• Not a good model for heterosexual trans
mission as shown in SHIV89.6P chimera model
• Supports HIV-2 replication but not HIV-1
• Baboon microglial cells can be infected by SHIV chimera with 
strong tropism for baboon PBMC but not for rhesus macaque 
PBMC.
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Animal model Species Cons Pros Retroviral study sub-types
Genetic comparison of non human primates in HIV research
Cons Opportunities provided by the NHP models in studies 
of HIV eradication
Pros
• High cost, maintenance and 
availability.
• Have limitated suitability for 
vaccine studies.
• SIV differs from HIV in genetic 
organization especially the Vpx 
gene of SIV and Vpu of HIV
• Simian AIDS generally develops 
within 6–12 months while the 
human AIDS develops after sev-
eral years of infection with HIV
• Identity, dose, and route of virus challenge known.
• Control for various clinical parameters that are 
virtually impossible to control in humans (time of 
infection, duration of ART etc).
• Comprehensive cellular and anatomic characteriza-
tion of both active and persistent reservoirs (includ-
ing elective necropsy).
• Pilot trials of in vivo eradication conducted in a 
timely and controlled fashion; treatment interruption 
is possible.
• Testing of “risky” interventions (i.e., cell depletion 
experiments, stem cell-based interventions etc).
• Steady environmental conditions can be applied for long periods 
therefore enhancing the chances to detect genetic effects
• Varying environmental settings can be imposed sequentially on 
NHP in order to characterize genotype-environment interactions;
• Possibility of testing genetic hypotheses in a prospective selective 
mating
• Important and needed invasive and terminal experiments can be 
conducted and validated
Table 1. Advantages and disadvantages of non-human primate models used in HIV-1 research.
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In the model, co-infection with BCG and SIV hastened the progression to AIDS [30] and 
reveals severe diminution of CD4+ T cells, loss of BCG-specific T cell responses, and reactiva-
tion of the clinically latent BCG infection into a TB-like disease as reported by Shen et al. [31]. 
M. tuberculosis reactivation in SIV-infected macaques is linked with peripheral T-cell deple-
tion instead of viral load [32].
3.2. Other primates
Chimpanzees support productive infection, but the disease does not occur for at least 
10 years. Alter et al.’s [33] investigative study was designed to determine the possibility of 
using a transmissible agent in humans with capability to induce AIDS in non-humans thus 
established an animal model in which the pathogenesis, treatment regimen, and prevention 
of AIDS could be studied (Table 1 and Figure 1). This early attempt pre-dates the virologic 
investigations that linked human AIDS to a type C retrovirus [33]. The NHP models have 
recorded tremendous successes, the limitations observed notwithstanding (Table 2).
Interestingly, Baboons can support replication of certain strains of HIV-2, but difficult with 
HIV-1 strains (Table 1). It has been shown that HIV infection replicates mainly in the T-cells, 
with limited or no activity in the monocytes or macropahges, CSF or brain of Baboons and 
macaque monkeys [34–36].
3.3. Mice
For better assessment of the HIV-linked clinical presentations, murine models have been 
developed and proved a better tool in elucidating the mechanism of disease progression. 
Equally giving lead to scientific direction as against non-human primates [37] geared toward 
the future of HIV drug and vaccine development [38]. Besides that, it is usually costly to work 
with the non-human primates (large animals), which further underscores the necessity for 
murine models [9].
Evaluation Species Study outcome Drug
Efficacy and toxicology Macaques Long term-highdose HIV treatments had 
adverse effects not found using short term-
high dose treatment
Tenofovir
Prophylactic treatment with 
anti-virals
Macaques The effectiveness of prophylaxis in blocking 
HIV infection as seen in the treatment for 
occupational exposures.
Various
Mother-to-fetus transmission, and 
fetal prophylaxis
Macaques Provided guidelines for antiviral treatment 
in HIV positive pregnant mothers
Tenofovir and AZT
Vaccine efficacy in SHIV 89.6p, a 
hybrid SIV, genetically engineered 
from HIV
Macaques The Monkeys were not protected against 
infection with SHIV however, they did have 
lower viral
MRK-Ad5
Table 2. Successful clinical testing conducted in NHP models.
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3.3.1. Murine AIDS
In many ways, murine AIDS (or MAIDS) and human AIDS are similar. Immunological analy-
sis and genetic studies reveal resistant gene(s) in the H-2 complex of mice, an indication that 
genetic differences in mice could modify features of HIV disease. The defective murine leu-
kemia virus is the major etiologic agent of MAIDS, which seems to be able to induce disease 
in the absence of virus replication. Target cell proliferation and oligoclonal expansion are 
induced by the virus, which suggests repressed immunity seen in mice thus referred to as 
paraneoplastic syndrome. This is further supported by the good response(s) of MAIDS mice 
to antineoplastic agents. This animal model is useful in demonstrating the emergence of novel 
hypotheses about AIDS, including the roles of defective HIV and HIV replication in the pro-
gression of the disease, and also the importance of identifying the HIV targeted cells in vivo.
Although MAIDS and AIDS are triggered by retroviruses of different classes, the availability 
of a model in small, accessible animal species with elaborated genetics is beneficial in under-
standing the pathogenesis of AIDS especially in cases where one or more of the affected cel-
lular and molecular pathways are common in both diseases [39].
3.3.2. Genetic modifications/gene manipulations
Potash et al. [40] designed a model of HIV-1 infection of mice for the study of viral replica-
tion, its pathogenesis and control. The team substituted the coding region of gp120 in HIV-1/
NL4–3 with gp80 from ecotropic murine leukemia virus, which infects only rodents, targeted 
at infecting rodents with HIV-1 in rodents. The EcoHIV was developed through the chimeric 
virus construct, which productively infected lymphocytes in mice, but failed to do the same 
in human lymphocyte culture. It was recorded that immunocompetent adult mice were easily 
prone to infection by a single dose EcoHIV inoculant as the demonstrated by viral detection 
in lymphocytes in the spleen, brain cells and peritoneal macrophages. The passage in culture, 
and induction of antibodies to HIV-1 Gag and Tat showed that the animal produced virus was 
indeed infectious and immunogenic, respectively.
3.3.3. Transgenic mice
Mice are not susceptible to HIV infection due to the virus specificity for the human cell. These 
would have otherwise been ideal models, however, owing to the large diverse tools and wide 
knowledge about the rodent immunity. To circumvent limitation in mice (Table 3), comple-
mentary mouse models have thus been developed over the years targeting specific genes 
(Table 4). Using these models, the more important features of HIV infections and M. tubercu-
losis can be replicated in mice (e.g. virus replication in splenic lymphocytes, peritoneal macro-
phages and brain tissue; typical TB granuloma formation; immune repression and/or chronic 
immune stimulation; and susceptibility to systemic, vaginal, and rectal infection by HIV) [24].
Mice modified genetically are often used for research and/or simply as an animal model of 
human diseases. The use of genetic engineering tools has greatly improved the ability to 
develop various mouse models important to preclinical research. With the recent develop-
ments in gene editing technologies, it is now possible to generate quickly highly adjustable 
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mouse models tailored to research needs. Mouse is still putatively the preferred animal model 
used in drug discovery and therapeutic agent development [52]. Below are some specific 
examples of genetically modified mouse model backgrounds which resulted from targeted 
mutations of specific mouse genes as presented in Table 4.
3.3.3.1. NOD/SCID mice
Since the early 2000s, a series of immune-deficient mice suitable for developing humice have 
been successively designed through the introduction of IL-2Rγnull gene (e.g. NOD/SCID/
γcnull and Rag2nullγcnull mice) using various genomic approaches. Mouse backgrounds serve 
as the basic genetic modified rodent from which other disease models are generated mostly 
by further modification and/or by human tissue engraftment. These mice were generated by 
genetically introducing human cytokine genes into NOD/SCID/γcnull and Rag2nullγcnull mouse 
backgrounds [52]. There are other models that rely on the transplantation of human tissues 
into the SCID mice, and they are referred to as the SCID-hu mouse model.
Animal 
Model
Parameters HIV/SCID-hu HIV/hu-HSC HIV/BLT Reference
Mice • Sample size
• Anatomical comparison with 
humans
• Similarity of infective agent 
to HIV
• Infection manifestation in 
comparison with human/HIV
• Availability for experimental 
infection in controlled condi-
tions vis-à-vis route and dose 
of virus inoculation, drug 
regimens etc.
• Ability to deplete major 
immune components
• Reservoir comparison to 
human/HIV
• Cost of maintenance com-
pared to NHP
• Methods mouse model 
development
• Timeframe needed for mouse 
development
• Cellular composition during 
reconstitution
• Degree of colonization
• Length infection sustained
Small
Different same
Similar
Yes
Yes
Yes
Similar
Minimal
SCID mice 
implanted with 
fetal human 
thymus/live.
5–7 months from 
time of birth
T cells
Only thymus/live 
implant
Grafts last almost 
12 months
Small
Different 
same
Similar
Yes
Yes
Yes
Similar
Minimal
NOD/
NSG mice 
irradiated and 
injected with 
human HSCs
2–3 months
T & B cells, 
DCs
Murine lymph 
organs and 
bone marrow
6–7 months
Small
Different same
Similar
Yes
Yes
[41]
[42–44]
[45–48]
[46, 49]
[47, 50, 51]
Yes
Similar
Minimal
NOD/SCID mice 
irradiated & 
implanted with fetal 
human thymus/live 
plus injection with 
HSCs
5–7 months
T & B cells, 
monocytes, 
macrophages, NK 
cells, DCs
Murine lymph 
organs, rectum, 
vagina, gut, bone 
marrow
Over 12 months
Table 3. Comparison of major mice chimeric models used in HIV-1 research.
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Earlier versions of humanized mice were developed mainly to study HIV-1 infection espe-
cially in modeling for immune-pathogenesis [53, 54], although the SCID-hu Thy/Liv model 
is still used to test for antiviral drugs [55]. In the improved humanized mice strains, several 
HIV-1 strains have been successfully used for HIV infection in the developed mouse model, 
and these include CCR5-tropic [56], CXCR4-tropic and dual-tropic (NL4-R3A) viruses [56]. 
Obviously, HIV-1 infection can be established in immune-deficient mouse models by inoc-
ulation through various routes of entry, namely intraperitoneal, intravenous and/or muco-
sal routes [57, 58]. Various research reports have established sustained viral replication and 
depletion of CD4+ T-cell using the routes of infection.
Gene name Characteristics
B2m
beta-2 microglobulin
This is required for normal expression of major histocompatibility class I proteins which 
displays viral and self-antigens to responsive T cells and secondly for CD8+ T cell 
maturation and NK cell development.
Foxn1
forkhead box N1, formerly 
Hfh11
Foxn1nu mutation is generally known as nude mutation. Homozygote (nu/nu) type lack a 
thymus that is they are ‘hypothymic’/‘athymic’ and thus are T cell deficient. Their responses 
to thymus-dependent antigens are poor. However, the allogenic and xenogenic grafts 
though may have NK activity show evidence of leakiness.
 Greatly increased susceptibility to infection.
Il2rg
interleukin 2 receptor, 
gamma chain
The Il2rg is required for IL2, IL4, IL7, IL9, IL15, and IL21 high-affinity binding and signaling. 
It is required in mediating susceptibility to thymic lymphomas in mice. Mostly observed 
is the Il2rg deficiency that blocks the development of NK cells and the resultant defects in 
innate immunity.
Myd88
myeloid differentiation 
primary response gene 88
Myd88 is critical adaptor protein utilized by all TLRs (except TLR 3) to activate 
transcription factor NF-κB in innate immunity signal transduction. Myd88 mutation leads 
to decreased innate responsesespecially neutrophils, macrophages,
hematopoietic, molecular signaling, and apoptotic abnormalities.
Prf1
perforin 1
Prf1 is a pore-forming protein that is an important component of the lytic pathway by 
which NK and CD8+ lymphocytes kill targeted cells.
Prkdc
protein kinase, DNA-
activated, catalytic 
polypeptide
The scid mutation in the Prkdc gene means severe combined immunodeficient. Prkdc 
plays a role in repairing double-stranded DNA breaks and in recombining the variable 
(V), diversity (D), and joining (J) segments of immunoglobulin and T-cell receptor genes. 
Homozygous (scid/scid) mutants have no mature T and B cells, cannot mount cell-mediated 
and humoral adaptive immune responses, do not reject allogeneic and xenogeneic grafts, 
and are useful cancer research models. The disadvantage is its leakiness as some functional 
B and T cells as they age, in non-SPF conditions. They cannot be as thoroughly irradiated as 
other immunodeficient models before being engrafted renders NOD mice diabetes-free.
Rag1
recombination activating 
gene 1
Rag1 is essential for the V(D)J gene rearrangements that generate functional antigen 
receptors in T and B cells; homozygous Rag1tm1Mom mutants have no mature, functional T 
and B cells. The Rag1tm1Mom mutation on the NOD background renders NOD mice diabetes-
free. However, aging NOD.129S7(B6)-Rag1tm1Mom/J mice develop B cell lymphomas at a high 
frequency.
Ticam1
Trif
Toll-like receptor adaptor molecule 1. It is an adapter protein used by TLR 3 to activate 
transcription factor NF-κB in innate i immunity signal transduction. Its mutation leads to 
decreased innate responses especially when combined with Myd88 mutation.
Table 4. Common genetic mutations found in mouse models and their functions (source: Ibeh et al. [52]).
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Evidently, Nie et al. have shown similar depletion of CD45RAþ naive and CD45RA + effector/
memory CD4þT lymphocytes by CXCR4- tropic HIV-1 in humanized mouse as were observed 
in HIV-1 patients. Similarly, the preferential depletion of CD45RA + CD4þT lymphocytes by 
CCR5-tropic HIV-1 was also observed. Further reports on humanized mice have shown its use-
fulness as a tool for studying various aspects of HIV-1 infection namely the roles of regulatory 
T cells (Tregs) [57], dendritic cells (pDCs) revealing the pathophysiology of human DC subsets 
[59] and pDC instigator function during disease initiation [60], HIV-1 immuno-pathogenesis 
[54, 61, 62], development of new antiviral therapy [6, 63], mucosal transmission, microbicide 
development [64] and currently in studying latent HIV infections. Latent HIV infections can 
now be established in a mouse model in the presence of administered ARV [65, 66].
3.3.3.2. BLT mice
Consequently, latency has been successfully generated in humanized BLT mice [67, 68]. 
Available report has shown that poly lactic-co-glycolic acid (PLGA) nanoparticles with encap-
sulated rilpivirine (an anti-retoviral drug) coated reproductive tract offered significant protec-
tion to BLT humanized mouse model from a vaginal high-dose HIV-1 challenge [68]. Several 
improvements of humice models with an enhanced human immune cell reconstitution espe-
cially the female genital tract tissues create a potential mice, susceptible to intravaginal HIV 
infection. This type of mouse model will enable studies on mechanisms involved in HIV 
transmission in vivo and represent powerful tool for studying hematopoiesis, inflammatory 
disease and viral host-pathogen interactions. Several potent HIV vaccines have been put on 
trial and enjoyed a well-publicized but prematurely terminated results due to high frequency 
of seroconversions among vaccine recipients [69, 70]. Previously, the only known model for 
HIV testing is infection of rhesus macaques with simian immunodeficiency virus (SIV) which 
has provided an excellent non-human primate model for studying HIV pathogenesis [71]. 
This model, however, has three major disadvantages despite its application in transmitting 
HIV experimentally to rhesus macaques across the cervicovaginal or rectal mucosa. The estab-
lished scenario makes it possible to test for microbicides and engages in laboratory study of 
mucosal HIV transmission. First, they are costly both in procurement and housing (limited 
number of primate facility globally) and is in high demand; secondly, SIV differs from HIV in 
genetic organization especially the Vpx gene of SIV and Vpu of HIV and lastly, while simian 
AIDS generally develops within 6–12 months of infection, the human AIDS develops after 
several years of infection with HIV (Table 1). However, these limitations serve as impediments 
in the search for an appropriate model of HIV drug testing and disease study, the transgenic 
mice model has overcome these feared problems associated with the SIV model. Mice have 
the utmost advantages of being inexpensive, have high reproductive capacity and may be 
housed in large numbers in a fairly small facility [72]. Furthermore, conduct of experimenta-
tion can be done in large numbers and in replicates. The severe combined immune deficiency 
mouse engrafted with human peripheral blood mononuclear cells (hu-PBL-SCID) could be 
co-engrafted with xenografts containing the dual of human fetal thymus and liver tissue 
(SCID-hu thy/liv)/(SCID-hu thy/liv), and this model is widely applied in preclinical evaluation 
of antiretroviral therapy [55, 58]. In another study, Denton et al. supported these findings and 
showed that the female reproductive tissues in BLT mice are adequately reconstituted with 
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HIV-susceptible human CD4þT cells, as well as other relevant populations [67]. Similarly, 
Dagur et al. in a current study demonstrated dual reconstitution in TK-NOG mouse model as 
a possible platform to investigate hepatocyte-related HIV-1 immunopathogenesis [73].
3.3.3.3. Other examples
The human hematopoietic progenitor cells (CD34+) from human cord blood are used to recon-
stitute the immune system of immune-deficient mice also known as humanized mouse [41]. 
An additional feature or rather advancement incorporates a fragment of the fetal human thy-
mus engraftment, which performs functionally as a human thymus. The significance of this is 
to allow for a more proper positive/negative T-cell selection previously not obtainable from 
the original model [74]. Immunologi and virologic parameters such as CD4+ cell depletion, 
extent of viremia, and co-receptor-mediated tropism were all observed in HIV infection of 
humanized experimental mice [74, 75]. The humice demonstrated transplanted human cells 
in mucosal linings therefore, most possibly get infected by intravaginal and/or intrarectal 
routes [76]. This model is used to evaluate novel approaches in HIV prevention and treat-
ment options including human-neutralizing antibodies, usage of prophylactic anti-retroviral 
therapies, and T cell-specific siRNA transfer [77]. The effect of M. tuberculosis infection on the 
induction of HIV gene expression has been studied with HIV transgenic mice integrating the 
entire viral genome [78]. In this model, viral gene expression was triggered by M. tuberculosis 
and suppressed after anti-mycobacterial chemotherapy [78].
4. Model suitable for vaccine trials
The question of whether or not there should be a standardized model is the basis on which 
the current controversies in HIV research rest on [26]. Differences in SIV and SHIV replication 
in the rhesus macaque, cynomolgous and pigtailed macaques’ species have been observed 
and is favored in the design of experimental models depending on the question raised [40]. 
For vaccine research, the rhesus does present the ideal for pathogenesis research; however, 
demanding for its use as a standard does present problems the current wave is to base con-
siderations on the transgenic mice models. Besides, vaccine testing in more than one species 
of macaques with similar vaccine modalities provides an opportunity to compare outcomes 
thus increasing confidence of research reproducibility [79].
Regulatory authorities require vaccine candidates to undergo preclinical evaluation in animal 
models before they enter the clinical trials in humans [80]. The overarching goal of a new 
vaccine is to stimulate the immune system to elicit an effective immune response against the 
pathogen it has been designed for, and currently no alternatives to live animal use currently 
exist for evaluation of this response despite advances in computational sciences for the search 
of an in-silico model [80].
Integral studies such as elucidation of immune protection mechanism, optimizing route and 
constitutions of vaccines; determining the onset and duration of immunity, as well as satis-
fying safety and efficacy requirements of the new vaccines, must be done in an integrated 
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living system [80]. As discussed earlier, a standardized animal model that provides all the 
information required for advancing a new vaccine through the preclinical stage has still not 
been met and even if it were, it is still bereft with problems bordering on bioethics. Current 
trend suggests that humanized mice (Table 3) more accurately predict vaccine outcomes that 
approximate humans.
5. HIV preclinical vaccine trials and predictive biomarker discovery 
in animal models
To accelerate effort in bridging the translational gap between preclinical evaluation and clini-
cal trials, it is pertinent to make animal model testing more clinical trial like. It is important 
that clinical endpoints may not be easily established in animal models because of the use of 
questionnaires to derive the quality of life issues from end users and cannot be replicated in 
experimental animals; however, there are recent attempts to model pain questionnaires in 
animals [81]. Obviously, animal models could be designed to use other endpoints that relate 
or translate into the expected endpoints of clinical trials. The humanized NSG among all 
other models have been successfully used for multiple in vivo preclinical validation studies. 
Potentially tested areas of validation include: (1) activation of human NK cells with an IL-15 
superagonist to inhibit acute HIV infection; (2) delivering anti-CCR5 and antiviral silencing 
RNAs (siRNA) direct delivery to T cells in order to control viral replication and prevent CD4+ 
T cell loss; (3) provision of prophylactic protection from HIV infection through induction of 
neutralizing anti-HIV monoclonal antibodies and (4) suppression of viral replication through 
introduced engineered HSCs that expresses an HIV-specific T cell receptor (TCR).
It is possible to design an integrated preclinical approach using PDX models organized with 
systems biology to enable the discovery and development of predictive biomarkers in order to 
classify clinical tumor responsiveness to a novel agent [82]. Peradventure the classifier achieved 
a high level of accuracy in the experiment, and biomarker-driven clinical trials could be devel-
oped based on the prevalent rate of the identified biomarkers and their link with efficacy.
6. Next generation models
The actual mechanism of sexual transmission is not precisely defined. What is known, how-
ever, is that HIV must be transmitted via the mucosal surfaces of the genital tract in both hetero- 
and homosexual cases [83]. The fact that some individuals remain uninfected despite multiple 
exposures, whereas others get infected after an exposure to HIV-infected semen further con-
founds the situation. An animal model adapted to mucosal transmission of the virus would 
aid elucidation of the mechanisms and dose of virus required for transmission and provide 
a system for testing pharmacologic and biologic cofactors that may affect HIV transmission.
Although intravenous inoculation of SIV into macaques is a near perfect model for studies of 
pathogenesis, this route is not appropriate for studying factors involved in the sexual transmission 
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of HIV. In one of the earliest experiments on the subject(macaques) [73], an animal model for the 
heterosexual transmission of HIV was developed by applying SIV onto the genital mucosa of both 
mature and immature male and female rhesus macaques. The study suggests that in the genital 
tract, the mucous membrane acts as a barricade to SIV infections as well as the non-involvement 
of spermatozoa and seminal plasma for genital HIV transmission.
Recent animal model research has focused on: (1) refinement of existing models and the devel-
opment of new ones; (2) development of a model in response to latency especially HIV reservoir 
and immune perseverance and (3) evaluation of vaccine candidate that would elicit broadly 
neutralizing antibodies. As discussed in the chapter, a suitable and cost-effective animal model 
for HIV has been a goal spanning three decades with important milestones accomplished.
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